Granted Patent
B2
US 12,465,641 · App. 18/228,770 · Granted Nov 11, 2025
Chimeric antigen receptor therapies for treating solid tumors
Inventors:
Dina Schneider (Potomac, MD); Peirong Hu (Ijamsville, MD); Tri Minh Tran (Frederick, MD); Brittany Steimle (Gaithersburg, MD); Aldo Sotelo (Sandy, UT)
Assignee:
LENTIGEN TECHNOLOGY, INC.
A61K40/421A61K40/11A61K40/31A61K40/4202A61K40/4255A61P35/00C07K14/7051C07K16/28C07K16/2803C07K16/2827C07K16/30C12N15/86C07K2319/03C12N2740/15043
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Novel anti-effector moiety antibodies or antigen binding domains thereof and CARs that contain such effector moiety antigen binding domains, either with or without one or more booster elements, and host cells expressing the receptors, and nucleic acid molecules encoding the receptors are provided herein, as well as methods of use of same in a patient-specific immunotherapy that can be used to treat solid tumor cancers and other diseases and conditions.
Claims (10)
1 . A method of treating a ROR1 + -cancer in a subject in need thereof, the method comprising administering to the subject having the ROR1 + -cancer a pharmaceutical composition comprising an anti-tumor effective amount of a population of T cells, wherein the T cells comprise a constitutive promoter operably linked to a nucleic acid sequence that encodes a single chimeric antigen receptor (CAR) with one or more booster elements, a tandem CAR with one or more booster elements, a multi-targeting CAR with one or more booster elements, or a DuoCAR with one or more booster elements, wherein the CAR of the single CAR with one or more booster elements, the tandem CAR with one or more booster elements, the multi-targeting CAR with one or more booster elements, or the DuoCAR with one or more booster elements comprises the amino acid sequence of SEQ ID NO: 152, 154, 156, 160, 162, 164, 174, 176, 178, 180, 182, 184, 192, 194, 196, 198, 227, 233, 235, 237, 239, 241, 243, 252, 254, or 256, wherein the T cells are T cells of the subject having the ROR + -cancer.
2 . The method of claim 1 , wherein the T cells are T cells of a human having a hematological ROR1 + -cancer.
3 . The method of claim 2 , wherein the hematological ROR1 + -cancer is leukemia or lymphoma.
4 . The method of claim 3 , wherein the leukemia is acute myeloid leukemia (AML), blastic plasmacytoid dendritic cell neoplasm (BPDCN), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), acute lymphoblastic T cell leukemia (T-ALL), or acute lymphoblastic B cell leukemia (B-ALL).
5 . The method of claim 3 , wherein the lymphoma is mantle cell lymphoma, non-Hodgkin's lymphoma or Hodgkin's lymphoma.
6 . The method of claim 2 , wherein the hematological ROR1 + -cancer is multiple myeloma.
7 . The method of claim 1 , wherein the ROR1 + -cancer is an adult carcinoma, wherein the adult carcinoma is an oral and pharynx cancer, a digestive system cancer, a respiratory system cancer, a bone and joint cancer, a soft tissue cancer, a skin cancer, a tumor of the central nervous system, a cancer of the breast, a cancer of the genital system, a cancer of the urinary system, a cancer of the eye and orbit, a cancer of the endocrine system, a cancer of the brain and other nervous system, or any combination thereof.
8 . The method of claim 1 , wherein the T cells comprise a nucleic acid sequence that encodes a single ROR1 CAR with one or more booster elements, wherein the CAR of the single ROR1 CAR with one or more booster elements comprises the amino acid sequence of SEQ ID NO: 160, SEQ ID NO: 162, SEQ ID NO: 164, SEQ ID NO: 192, SEQ ID NO: 194, SEQ ID NO: 196, SEQ ID NO: 233, SEQ ID NO: 235, SEQ ID NO: 237, SEQ ID NO: 239, SEQ ID NO: 241, or SEQ ID NO: 243.
9 . The method of claim 1 , wherein the T cells comprise a nucleic acid sequence that encodes a tandem ROR1-MSLN CAR with one or more booster elements, wherein the CAR of the tandem ROR1-MLSN CAR with one or more booster elements comprises the amino acid sequence of SEQ ID NO: 176, SEQ ID NO: 178, or SEQ ID NO: 180.
10 . The method of claim 1 , wherein the T cells comprise a nucleic acid sequence that encodes a ROR1-MSLN DuoCAR with one or more booster elements, wherein the CAR of the ROR1-MSLN DuoCAR with one or more booster elements comprises the amino acid sequence of SEQ ID NO: 182 or SEQ ID NO: 184.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 10, 2024
From: SCHNEIDER, DINA; HU, PEIRONG; TRAN, TRI MINH; STEIMLE, BRITTANY; SOTELO, ALDO
To: LENTIGEN TECHNOLOGY, INC.
Reel/Frame 068863/0679 →
Continuity (4)
Continuation
PCTUS2023029008
· Jul 28, 2023
Provisional Application
63433632
· Dec 19, 2022
Provisional Application
63393088
· Jul 28, 2022
References Cited (250)
US 3060165A
· Craigl. et al.
· 1962
[cited by applicant]
US 3896111A
· Kupchan et al.
· 1975
[cited by applicant]
US 4137230A
· Hashimoto et al.
· 1979
[cited by applicant]
US 4235871A
· Papahadjopoulo et al.
· 1980
[cited by applicant]
US 4248870A
· Miyashita et al.
· 1981
[cited by applicant]
US 4256746A
· Miyashita et al.
· 1981
[cited by applicant]
US 4260608A
· Miyashita et al.
· 1981
[cited by applicant]
US 4265814A
· Hashimoto et al.
· 1981
[cited by applicant]
US 4294757A
· Asai
· 1981
[cited by applicant]
US 4307016A
· Asai
· 1981
[cited by applicant]
US 4308268A
· Miyashita et al.
· 1981
[cited by applicant]
US 4308269A
· Miyashita et al.
· 1981
[cited by applicant]
US 4309428A
· Miyashita et al.
· 1982
[cited by applicant]
US 4313946A
· Powell et al.
· 1982
[cited by applicant]
US 4315929A
· Freedman et al.
· 1982
[cited by applicant]
US 4317821A
· Miyashita et al.
· 1982
[cited by applicant]
US 4322348A
· Asai et al.
· 1982
[cited by applicant]
US 4331598A
· Hasegawa et al.
· 1982
[cited by applicant]
US 4361650A
· Asai et al.
· 1982
[cited by applicant]
US 4362663A
· Kida et al.
· 1982
[cited by applicant]
US 4364866A
· Asai et al.
· 1982
[cited by applicant]
US 4371533A
· Akimoto et al.
· 1983
[cited by applicant]
US 4424219A
· Hashimoto et al.
· 1984
[cited by applicant]
US 4450254A
· Isely et al.
· 1984
[cited by applicant]
US 4486414A
· Pettit
· 1984
[cited by applicant]
US 4501728A
· Geho et al.
· 1985
[cited by applicant]
US 4689401A
· Ferris
· 1987
[cited by applicant]
US 4816444A
· Pettit et al.
· 1989
[cited by applicant]
US 4837028A
· Allen
· 1989
[cited by applicant]
US 4879278A
· Pettit et al.
· 1989
[cited by applicant]
US 4880935A
· Thorpe
· 1989
[cited by applicant]
US 4902505A
· Pardridge et al.
· 1990
[cited by applicant]
US 4957735A
· Huang
· 1990
[cited by applicant]
US 4978744A
· Pettit et al.
· 1990
[cited by applicant]
US 4986988A
· Pettit et al.
· 1991
[cited by applicant]
US 5004697A
· Pardridge
· 1991
[cited by applicant]
US 5019369A
· Presant et al.
· 1991
[cited by applicant]
US 5055303A
· Riley
· 1991
[cited by applicant]
US 5076973A
· Pettit et al.
· 1991
[cited by applicant]
US 5079163A
· Piatak et al.
· 1992
[cited by applicant]
US 5122368A
· Greenfield et al.
· 1992
[cited by applicant]
US 5138036A
· Pettit et al.
· 1992
[cited by applicant]
US 5188837A
· Domb
· 1993
[cited by applicant]
US 5208021A
· Johnson et al.
· 1993
[cited by applicant]
US 5254342A
· Shen et al.
· 1993
[cited by applicant]
US 5268164A
· Kozarich et al.
· 1993
[cited by applicant]
US 5271961A
· Mathiowitz et al.
· 1993
[cited by applicant]
US 5410024A
· Pettit et al.
· 1995
[cited by applicant]
US 5413797A
· Khan et al.
· 1995
[cited by applicant]
US 5416064A
· Chari et al.
· 1995
[cited by applicant]
US 5449752A
· Fujii et al.
· 1995
[cited by applicant]
US 5504191A
· Pettit et al.
· 1996
[cited by applicant]
US 5506206A
· Kozarich et al.
· 1996
[cited by applicant]
US 5514670A
· Friedman et al.
· 1996
[cited by applicant]
US 5521284A
· Pettit et al.
· 1996
[cited by applicant]
US 5530097A
· Pettit et al.
· 1996
[cited by applicant]
US 5534496A
· Lee et al.
· 1996
[cited by applicant]
US 5554725A
· Pettit
· 1996
[cited by applicant]
US 5599902A
· Pettit et al.
· 1997
[cited by applicant]
US 5622929A
· Willner et al.
· 1997
[cited by applicant]
US 5635483A
· Pettit et al.
· 1997
[cited by applicant]
US 5663149A
· Pettit et al.
· 1997
[cited by applicant]
US 5665860A
· Pettit et al.
· 1997
[cited by applicant]
US 5780588A
· Pettit et al.
· 1998
[cited by applicant]
US 5792458A
· Johnson et al.
· 1998
[cited by applicant]
US 5824805A
· King et al.
· 1998
[cited by applicant]
US 6034065A
· Pettit et al.
· 2000
[cited by applicant]
US 6214345B1
· Firestone et al.
· 2001
[cited by applicant]
US 6239104B1
· Pettit et al.
· 2001
[cited by applicant]
US 6323315B1
· Pettit et al.
· 2001
[cited by applicant]
US 6441163B1
· Chari et al.
· 2002
[cited by applicant]
US 6884869B2
· Senter et al.
· 2005
[cited by applicant]
US 7338929B2
· Debinski et al.
· 2008
[cited by applicant]
US 7498298B2
· Doronina et al.
· 2009
[cited by applicant]
US 7964566B2
· Doronina et al.
· 2011
[cited by applicant]
US 20020197266A1
· Debinski et al.
· 2002
[cited by applicant]
US 20110070248A1
· Ichikawa et al.
· 2011
[cited by applicant]
US 20110212088A1
· Sabbadini et al.
· 2011
[cited by applicant]
EP 0425235B1
· 1996
[cited by applicant]
EP 3730612
· 2020
[cited by applicant]
WO WO2004010957
· 2004
[cited by applicant]
WO WO2012079000
· 2012
[cited by applicant]
WO WO2013126726
· 2013
[cited by applicant]
WO WO2015105522
· 2015
[cited by applicant]
WO WO2018045325
· 2018
[cited by applicant]
WO WO2019090110
· 2019
[cited by applicant]
WO WO2020181164A1
· 2020
[cited by examiner]
WO WO2021102337
· 2021
[cited by applicant]
WO WO2021214270
· 2021
[cited by applicant]
WO WO2022150831
· 2022
[cited by applicant]
Ramaekers et al., Clin Chem Lab Med 2013. (Year: 2013).
[cited by examiner]
Struber et al. (Journal for ImmunoTherapy of Cancer 2020;8:e000676). (Year: 2020).
[cited by examiner]
Zhu et al. (Cancer Biology & Therapy 2019, vol. 20, No. 8, 1105-1112). (Year: 2019).
[cited by examiner]
Hudecek et al. (Cancer Immunol Res; 3(2); 125-35 (2014)). (Year: 2014).
[cited by examiner]
Melisi et al. (Cancer Chemotherapy and Pharmacology (2019) 83:975-991). (Year: 2019).
[cited by examiner]
Yang et al. (Molecular Therapy: Oncolytics vol. 17, pp. 571-585 (2020)). (Year: 2020).
[cited by examiner]
Carbone et al. (Seminars in Cancer Biology, 2004, 14: 399-405). (Year: 2004).
[cited by examiner]
Kean et al., (2018; Blood, pp. 2630-2639). (Year: 2018).
[cited by examiner]
Wang et al.(2015, Molecular Therapy pp. 184-191). (Year: 2015).
[cited by examiner]
Voskoglou-Nomikos et al., (Clinical Cancer Research, 2003, 9, 4227-4239). (Year: 2003).
[cited by examiner]
Assis-Mendonça et al. (BMC Cancer. Mar. 1, 2021;21(1):209, and supplemental Fig. 3). (Year: 2021).
[cited by examiner]
Wang et al. (Cellular Immunology 363 (2021) 104342). (Year: 2021).
[cited by examiner]
Srivastava et al., Cancer Cell 35, 489-503, (2019) with additional pp. e1-e8 and further pp. 1-12. (Year: 2019).
[cited by examiner]
Labanieh et al. (2022, Cell 185, 1745-1763, and additional pp. e1-e9; pp. 1-13). (Year: 2022).
[cited by examiner]
Tristan-Manzano et al. (Mol Ther Oncolytics. May 18, 2022;25:335-349 and Supplemental pp. 1-7). (Year: 2022).
[cited by examiner]
Weber et al. (Science. Apr. 2, 2021;372(6537):eaba1786 and supplemental pp. 1-40). (Year: 2021).
[cited by examiner]
Eyquem et al. (Nature. Mar. 2, 2017;543(7643):113-117, Methods and Extended Data pp. 1-14). (Year: 2017).
[cited by examiner]
Mary Gearing, Jan. 18, 2018, “Plasmids 101: Inducible Promoters,” Addgene blog, retrieved from the internet Apr. 5, 2025, pp. 1-5. (Year: 2018).
[cited by examiner]
Qin et al., PLoS ONE 5(5): e10611 (2010). (Year: 2010).
[cited by examiner]
Ahmad et al., “scFv antibody: principles and clinical application,” Journal of Immunology Research, Mar. 2012, 16 pages.
[cited by applicant]
Alabanza et al., “Armored BCMA CAR T cells eliminate multiple myeloma and are resistant to the suppressive effects of TGF-ß,” Frontiers in Immunology, Feb. 2022, 13:832645, 17 pages.
[cited by applicant]
Al-Lazikani et al., “Standard conformations for the canonical structures of immunoglobulins,” Journal of Molecular Biology, Nov. 1997, 273(4):927-48.
[cited by applicant]
Anderson et al., “The tumor microenvironment,” Current Biology, Aug. 2020, 30(16):R921-5.
[cited by applicant]
Baskar et al., “Unique cell surface expression of receptor tyrosine kinase RORI in human B-cell chronic lymphocytic leukemia,” Clinical Cancer Research, Jan. 2008, 14(2):396-404.
[cited by applicant]
Batlle et al., “Transforming growth factor-ß signaling in immunity and cancer,” Immunity, Apr. 2019, 50(4):924-40.
[cited by applicant]
Bielamowicz et al., “Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma, ” Neuro-oncology, Mar. 2018, 20(4):506-18.
[cited by applicant]
Bierer et al., “Cyclosporin A and FK506: molecular mechanisms of immunosuppression and probes for transplantation biology,” Current Opinion in Immunology, Oct. 1993, 5(5):763-73.
[cited by applicant]
Bird et al., “Single-chain antigen-binding proteins,” Science, Oct. 1988, 242(4877):423-6.
[cited by applicant]
Blazar et al., “Strategies to inhibit alloantibody production in alloprimed murine recipients of hematopoietic stem cell grafts,” American Journal of Transplantation, Apr. 2015, 15(4):931-41.
[cited by applicant]
Brentjens et al., “Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial,” Molecular Therapy, Apr. 2010, 18(4):666…
[cited by applicant]
Brown et al., “Stem-like tumor-initiating cells isolated from IL 13Rα2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T cells, ” Clinical Cancer Research, Apr. 2012, 18(8):2199, 22 pages.
[cited by applicant]
Capecchi, “High efficiency transformation by direct microinjection of DNA into cultured mammalian cells,” Cell, Nov. 1980, 22(2):479-88.
[cited by applicant]
Caruana et al., “Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes,” Nature Medicine, May 2015, 21(5):524, 18 pages.
[cited by applicant]
Clay et al., “Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity,” The Journal of Immunology, Jul. 1, 1999, 163(1):507-13.
[cited by applicant]
Daneshmanesh et al., “Orphan receptor tyrosine kinases RORI and ROR2 in hematological malignancies,” Leukemia & Lymphoma, Apr. 2013, 54(4):843-50.
[cited by applicant]
Derynck et al., “TGF-ß biology in cancer progression and tumor immunotherapy,” Nature Reviews Clinical Oncology, Jan. 2021, 18(1), 51 pages.
[cited by applicant]
Dubowchik et al., “Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs,” Pharmacology & Therapeutics, Aug. 1999, 83(2):67-123.
[cited by applicant]
Ellebrecht et al., “Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. ” Science, Jul. 2016, 353(6295):179-84.
[cited by applicant]
Felgner et al., “Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure,” Proceedings of the National Academy of Sciences, Nov. 1987, 84(21):7413-7.
[cited by applicant]
Fults et al., “Sustained-release of urease from a poloxamer gel matrix,” PDA Journal of Pharmaceutical Science and Technology, Mar. 1990, 44(2):58-65.
[cited by applicant]
Funatsu et al., “The complete amino acid sequence of the A-chain of abrin-a, a toxic protein from the seeds of Abrus precatorius,” Agricultural and Biological Chemistry, Apr. 1988, 52(4):1095-7.
[cited by applicant]
GenBank Acession No. AAA35664.1, “T lymphocyte surface glycoprotein (CD8-beta) precursor [Homo sapiens],” Apr. 27, 1993, 2 pages.
[cited by applicant]
Gill et al., “Chimeric antigen receptor T cell therapy: 25 years in the making, ” Blood Reviews, May 2016, 30(3):157-67.
[cited by applicant]
Gillespie et al., “Phase I open study of the effects of ascending doses of the cytotoxic immunoconjugate CMB-401 (hCTMO1-calicheamicin) in patients with epithelial ovarian cancer,” Annals of Oncology, Jun. 2000, 11(6):7…
[cited by applicant]
Goyal et al., “Inclusion of a furin-sensitive spacer enhances the cytotoxicity of ribotoxin restrictocin containing recombinant single-chain immunotoxins,” Biochemical Journal, Jan. 2000, 345(2):247-54.
[cited by applicant]
Graham et al., “A new technique for the assay of infectivity of human adenovirus 5 DNA,” Virology, Apr. 1973, 52(2):456-67.
[cited by applicant]
Grupp et al., “Chimeric antigen receptor-modified T cells for acute lymphoid leukemia, ” New England Journal of Medicine, Apr. 2013, 368(16):1509-18.
[cited by applicant]
Guedan et al., “Engineering and design of chimeric antigen receptors, ” Molecular Therapy-Methods & Clinical Development, Mar. 2019, 12:145-56.
[cited by applicant]
Hamers-Casterman et al., “Naturally occurring antibodies devoid of light chains,” Nature, Jun. 1993, 363(6428):446-8.
[cited by applicant]
Han et al., “Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges,” Journal of Hematology & Oncology, Dec. 2013, 6(1):1-7.
[cited by applicant]
Han et al., “Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy,” Journal of Hematology & Oncology, Dec. 2019, 12:1-0.
[cited by applicant]
Haso et al., “Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia,” Blood, The Journal of the American Society of Hematology, Feb. 2013, 121(7):1165-74.
[cited by applicant]
Hay et al., “Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy,” Blood, The Journal of the American Society of Hematology, Nov. 23, 2017, 130(21):22…
[cited by applicant]
He et al., “Co-expression of IL-7 improves NKG2D-based CAR T cell therapy on prostate cancer by enhancing the expansion and inhibiting the apoptosis and exhaustion,” Cancers, Jul. 2020, 12(7):1969, 17 pages.
[cited by applicant]
Henderson et al., “Comparison of the effects of FK-506, cyclosporin A and rapamycin on IL-2 production,” Immunology, Jul. 1991, 73(3):316, 16 pages.
[cited by applicant]
Holliger et al., “Diabodies: small bivalent and bispecific antibody fragments,” Proceedings of the National Academy of Sciences, Jul. 1993, 90(14):6444-8.
[cited by applicant]
Hudecek et al. “Receptor affinity and extracellular domain modifications affect tumor recognition by RORI-specific chimeric antigen receptor T cells,” Clinical Cancer Research, Jun. 2013, 19(12):3153-64.
[cited by applicant]
Huse et al., “Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda,” Science, Dec. 1989, 246(4935):1275-81.
[cited by applicant]
Huston et al., “Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in
[cited by applicant]
Ijntema et al., “Hydroxyapatite microcarriers for biocontrolled release of protein drugs,” International Journal of Pharmaceutics, Dec. 1994, 112(3):215-24.
[cited by applicant]
Johnson et al., “Anti-tumor activity of CC49-doxorubicin immunoconjugates,” Anticancer Research, Jul. 1995, 15(4):1387-93.
[cited by applicant]
Johnston et al., “Sustained delivery of interleukin-2 from a poloxamer 407 gel matrix following intraperitoneal injection in mice,” Pharmaceutical Research, Mar. 1992, 9:425-34.
[cited by applicant]
Jones et al., “Improving the safety of cell therapy products by suicide gene transfer,” Frontiers in Pharmacology, Nov. 2014, 5:254, 8 pages.
[cited by applicant]
Kao et al., “A cetuximab-mediated suicide system in chimeric antigen receptor-modified hematopoietic stem cells for cancer therapy,” Human Gene Therapy, Apr. 2019, 30(4):413-28.
[cited by applicant]
Katsarou et al., “Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence,” Science Translational Medicine, Dec. 2021, 13(623):eabh1962, 18 pages.
[cited by applicant]
Kindt et al. “Antibodies: Structure and Function, ” Kuby Immunology, 6th edition, W.H. Freeman and Co., Aug. 2006, p. 91.
[cited by applicant]
Kipps, “RORI: An orphan becomes apparent,” Blood, The Journal of the American Society of Hematology, Oct. 2022, 140(14):1583-91.
[cited by applicant]
Klein et al., “High-velocity microprojectiles for delivering nucleic acids into living cells, ” Nature, May 1987, 327(6117):70-3.
[cited by applicant]
Kloss et al., “Dominant-negative TGF-ß receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication,” Molecular Therapy, Jul. 2018, 26(7):1855, 13 pages.
[cited by applicant]
Kochenderfer et al., “B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells,” Blood, The Journal of the Ameri…
[cited by applicant]
Kumaresan et al., “Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection,” Proceedings of the National Academy of Sciences, Jul. 2014, 111(29):10660-5.
[cited by applicant]
Laird et al., “Isolation and characterization of tox mutants of corynebacteriophage beta, ” Journal of Virology, Jul. 1976, 19(1):220-7.
[cited by applicant]
Lau et al., “Conjugation of doxorubicin to monoclonal anti-carcinoembryonic antigen antibody via novel thiol-directed cross-linking reagents,” Bioorganic & Medicinal Chemistry, Oct. 1995, 3(10):1299-304.
[cited by applicant]
Lau et al., “Novel doxorubicin-monoclonal anti-carcinoembryonic antigen antibody immunoconjugate activity in vitro,” Bioorganic & Medicinal Chemistry, Oct. 1995, 3(10):1305-12.
[cited by applicant]
Lee et al., “Calicheamicins, a novel family of antitumor antibiotics, 3. Isolation, purification and characterization of calicheamicins beta 1Br, gamma 1Br, alpha 2I, alpha 3I, beta 1I, gamma 1I and delta 1I,” The Journ…
[cited by applicant]
Lee et al., “Clinical signs and symptoms in non-transfused patients with paroxysmal nocturnal hemoglobinuria from a Korean prospective PNH registry, ” Blood, Nov. 2013, 122(21):3720, presented at the American Society of…
[cited by applicant]
Lefranc et al., “IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains,” Developmental & Comparative Immunology, Jan. 2003, 27(1):55-77.
[cited by applicant]
Lehner et al., “Redirecting T cells to Ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection,” PloS one, Feb. 2012, 7(2):e31210, 12 pages.
[cited by applicant]
Li et al., “IL-7 and CCR2b co-expression-mediated enhanced CAR-T survival and infiltration in solid tumors,” Frontiers in Oncology, Oct. 2021, 11:734593, 9 pages.
[cited by applicant]
Lindo et al., “Befriending the hostile tumor microenvironment in CAR T-cell therapy,” Frontiers in Immunology, Feb. 2021, 11:618387.
[cited by applicant]
Liu et al., “Calcineurin is a common target of cyclophilin-cyclosporin A and Fkbp-FK506 complexes,” Cell, Aug. 1991, 66(4): 807-15.
[cited by applicant]
Lonberg et al., “Human antibodies from transgenic animals,” Nature Biotechnology, Sep. 2005, 23(9):1117-25.
[cited by applicant]
Lonberg, “Fully human antibodies from transgenic mouse and phage display platforms,” Current Opinion in Immunology, Aug. 2008, 20(4):450-9.
[cited by applicant]
Long et al., “Lessons learned from a highly-active CD22-specific chimeric antigen receptor,” Oncoimmunology, Apr. 2013, 2(4):e23621, 3 pages.
[cited by applicant]
Mabry et al., “Therapeutic bispecific antibodies: The selection of stable single-chain fragments to overcome engineering obstacles,” Idrugs: the Investigational Drugs Journal, Aug. 1, 2010, 13(8):543-9.
[cited by applicant]
Majzner et al., “Tumor antigen escape from CAR T-cell therapy,” Cancer Discovery, Oct. 2018, 8(10):1219, 9 pages.
[cited by applicant]
Milone et al., “Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo,” Molecular Therapy, Aug. 1, 2009, 17(8):1453, 13 pages.
[cited by applicant]
Morgan et al., “Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2,” Molecular Therapy, Apr. 2010, 18(4):843, 10 pages.
[cited by applicant]
Narayan et al., “PSMA-targeting TGFß-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial,” Nature Medicine, Apr. 2022, 28(4):724-34.
[cited by applicant]
NCBI ID No. NP_000130.1, “high affinity immunoglobulin epsilon receptor subunit beta isoform 1 [Homo sapiens],” Sep. 9, 2021, 4 pages.
[cited by applicant]
NCBI ID No. NP_000607.1, “T-cell surface glycoprotein CD4 isoform 1 precursor [Homo sapiens],” Jun. 12, 2022.
[cited by applicant]
NCBI ID No. NP_000617.1, “B-cell antigen receptor complex-associated protein beta chain isoform 1 precursor [Homo sapiens],” Apr. 16, 2022, 5 pages.
[cited by applicant]
NCBI ID No. NP_000723.1, T-cell surface glycoprotein CD3 delta chain isoform A precursor [Homo sapiens], Jun. 9, 2022, 4 pages.
[cited by applicant]
NCBI ID No. NP_000724.1, “T-cell surface glycoprotein CD3 epsilon chain precursor [Homo sapiens],” Jun. 8, 2022, 4 pages.
[cited by applicant]
NCBI ID No. NP_001552.2, “tumor necrosis factor receptor superfamily member 9 precursor [Homo sapiens],” Jun. 7, 2022, 4 pages.
[cited by applicant]
NCBI ID No. NP_001758.2, “T-cell surface antigen CD2 isoform 2 precursor [Homo sapiens],” Jun. 3, 2022, 5 pages.
[cited by applicant]
NCBI ID No. NP_001759.3, T-cell surface glycoprotein CD8 alpha chain isoform 1 precursor [Homo sapiens], Jun. 12, 2022, 4 pages.
[cited by applicant]
NCBI ID No. NP_001762.2, “B-cell receptor CD22 isoform 1 precursor [Homo sapiens],” Apr. 17, 2022, 7 pages.
[cited by applicant]
NCBI ID No. NP_001774.1, “B-cell antigen receptor complex-associated protein alpha chain isoform 1 precursor [Homo sapiens],” Jun. 8, 2022, 4 pages.
[cited by applicant]
NCBI ID No. NP_001806.2, “carcinoembryonic antigen-related cell adhesion molecule 3 isoform 1 precursor [Homo sapiens],” Feb. 27, 2022, 4 pages.
[cited by applicant]
NCBI ID No. NP_003318.1, “tumor necrosis factor receptor superfamily member 4 isoform 1 precursor [Homo sapiens],” Aug. 16, 2022, 4 pages.
[cited by applicant]
NCBI ID No. NP_004097.1, “high affinity immunoglobulin epsilon receptor subunit gamma precursor [Homo sapiens],” May 15, 2022, 3 pages.
[cited by applicant]
NCBI ID No. NP_006130.1, “T-cell-specific surface glycoprotein CD28 isoform 1 precursor [Homo sapiens],” May 22, 2022, 5 pages.
[cited by applicant]
NCBI ID No. NP_036224.1, “inducible T-cell costimulator precursor [Homo sapiens],” Apr. 17, 2022, 3 pages.
[cited by applicant]
NCBI ID No. NP_055022.2, “T-cell surface glycoprotein CD5 isoform 1 precursor [Homo sapiens],” Apr. 24, 2022, 4 pages.
[cited by applicant]
NCBI ID No. NP_932170.1, “T-cell surface glycoprotein CD3 zeta chain isoform 1 precursor [Homo sapiens],” Jun. 12, 2022, 4 pages.
[cited by applicant]
NCBI ID No. NP_000064.1, Mycolicibacterium smegmatis MC2 155, complete sequence, Apr. 11, 2022, 2 pages, 6 pages.
[cited by applicant]
Neville et al., “Enhancement of immunotoxin efficacy by acid-cleavable cross-linking agents utilizing diphtheria toxin and toxin mutants,” Journal of Biological Chemistry, Sep. 1989, 264(25):14653-61.
[cited by applicant]
Nicolson et al., “The interaction of Ricinus communis agglutinin with normal and tumor cell surfaces,” Biochimica et Biophysica Acta (BBA)-Biomembranes, May 1972, 266(2):543-7.
[cited by applicant]
Olsnes et al., “Mechanism of action of the toxic lectins abrin and ricin, ” Nature, Jun. 1974, 249(5458):627-31.
[cited by applicant]
Olsnes, “[35] Ricin and ricinus agglutinin, toxic lectins from castor bean,” Methods in Enzymology, Jan. 1978, (50):330-5.
[cited by applicant]
Park et al., “Treating cancer with genetically engineered T cells, ” Trends in Biotechnology, Nov. 2011, 29(11):550-7.
[cited by applicant]
Phillips et al., “Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate,” Cancer Research, Nov. 2008, 68(22):9280-90.
[cited by applicant]
Pietrobon et al., “Improving CAR T-cell persistence,” International Journal of Molecular Sciences, Oct. 2021, 22(19):10828, 27 pages.
[cited by applicant]
Poljak, “Production and structure of diabodies,” Structure, Dec. 1994, 2(12):1121-3.
[cited by applicant]
Porter et al., “Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia, ” New England Journal of Medicine, Aug. 2011, 365(8):725-33.
[cited by applicant]
Rathore et al., “Overproduction of fungal ribotoxin a-sarcin in
[cited by applicant]
Sadelain et al., “The basic principles of chimeric antigen receptor design,” Cancer Discovery, Apr. 2013, 3(4):388-98.
[cited by applicant]
Schneider et al., “A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines,” Journal for Immunotherapy of Cancer, Dec. 2017, 5(1):1-7.
[cited by applicant]
Schneider et al., “Trispecific CD19-CD20-CD22-targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models,” Science Translational Medicine, Mar. 2021, 13(586):eabc6401, 14 pages.
[cited by applicant]
Schubert et al., “Third-generation CAR T cells targeting CD19 are associated with an excellent safety profile and might improve persistence of CAR T cells in treated patients, ” Blood, Nov. 2019, 134(supp 1):51, 3 pages.
[cited by applicant]
Shalabi et al., “Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma,” Haematologica, May 2018, 103(5):e215, 4 pages.
[cited by applicant]
Sheriff et al., “Redefining the minimal antigen-binding fragment,” Nature Structural Biology, Sep. 1996, 3(9):733-6.
[cited by applicant]
Srivastava et al., “Immunogenic chemotherapy enhances recruitment of CAR-T cells to lung tumors and improves antitumor efficacy when combined with checkpoint blockade,” Cancer Cell, Feb. 2021, 39(2):193, 27 pages.
[cited by applicant]
Sterner et al., “CAR-T cell therapy: current limitations and potential strategies,” Blood Cancer Journal, Apr. 2021, 11(4):69, 11 pages.
[cited by applicant]
Stirpe et al., “Ribosome-inactivating proteins from plants: Present status and future prospects,” Bio/technology, Apr. 1992, 10(4):405-12.
[cited by applicant]
Subklewe et al., “Chimeric antigen receptor T cells: a race to revolutionize cancer therapy,” Transfusion Medicine and Hemotherapy, Feb. 2019, 46(1):15-24.
[cited by applicant]
Suzuki et al., “Engineering receptor-mediated cytotoxicity into human ribonucleases by steric blockade of inhibitor interaction,” Nature Biotechnology, Mar. 1999, 17(3):265-70.
[cited by applicant]
Tang et al., “TGF-ßinhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors,” JCI Insight, Feb. 2020, 5(4), 40 pages.
[cited by applicant]
Tedesco et al., “Biomarkers for predicting cytokine release syndrome following CD19-targeted CAR T cell therapy,” The Journal of Immunology, Apr. 2021, 206(7):1561, 13 pages.
[cited by applicant]
Thorpe et al., “New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo,” Cancer Research, Nov. 1987, 47(22):5924-31.
[cited by applicant]
Till et al., “Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells,” Blood, The Journal of the American Society of Hematology, Sep…
[cited by applicant]
Tumaini et al., “Simplified process for the production of anti-CD19-CAR-engineered T cells,” Cytotherapy, Nov. 2013, 15(11):1406-15.
[cited by applicant]
Tzavlaki et al., “TGF-ß Signaling,” Biomolecules, Mar. 2020, 10(3):487, 38 pages.
[cited by applicant]
Wagner et al., “CAR T cell therapy for solid tumors: bright future or dark reality?,” Molecular Therapy, Nov. 2020, 28(11):2320-39.
[cited by applicant]
Walsh et al., “Multi-specific CAR targeting to prevent antigen escape,” Current Hematologic Malignancy Reports, Oct. 2019, 14:451-9.
[cited by applicant]
Ward et al., “Binding activities of a repertoire of single immunoglobulin variable domains secreted from
[cited by applicant]
Winter et al., “Humanized antibodies,” Immunology Today, Jun. 1993, 14(6):243-6.
[cited by applicant]
Yeku et al., “Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment,” Scientific Reports, Sep. 2017, 7(1):10541.
[cited by applicant]
Yu et al., “The biosynthetic gene cluster of the maytansinoid antitumor agent ansamitocin from Actinosynnema pretiosum,” Proceedings of the National Academy of Sciences, Jun. 2002, 99(12):7968-73.
[cited by applicant]
Yvon et al., “Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells,” Clinical Cancer Research, Sep. 15, 2009, 15(18):5852-60.
[cited by applicant]
Zhang et al., “Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors,” Science China Life Sciences, Apr. 2016, 59:340-8.
[cited by applicant]
Zhang et al., “RORI is expressed in human breast cancer and associated with enhanced tumor-cell growth,” PloS one, Mar. 2012, 7(3):e31127, 12 pages.
[cited by applicant]
Zhang et al., “The onco-embryonic antigen RORI is expressed by a variety of human cancers,” The American Journal of Pathology, Dec. 2012, 181(6):1903-10.
[cited by applicant]
Zhao et al., “A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity,” The Journal of Immunology, Nov. 2009, 183(9):5563…
[cited by applicant]
Zhao et al., “Bioorthogonal equipping CAR-T cells with hyaluronidase and checkpoint blocking antibody for enhanced solid tumor immunotherapy,” ACS Central Science, Apr. 2022, 8(5):603-14.
[cited by applicant]
Zhao et al., “Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines, ” The Journal of Immunology, Apr. 2005, 174(7):4415-23.
[cited by applicant]
International Search Report and Written Opinion in International Appln. No. PCT/US2023/029008, mailed on Mar. 21, 2024, 26 pages.
[cited by applicant]
PCT International Preliminary Report on Patentability in International Appln. No. PCT/US2023/029008, mailed on Jan. 28, 2025, 14 pages.
[cited by applicant]